Oral Factor XIa Inhibitor Milvexian Fails to Demonstrate Impressive Results for Preventing Stroke
People with factor XI deficiency have lower rates of ischemic stroke and infrequent spontaneous bleeding, presenting an essential role in thrombosis than in hemostasis. Milvexian, an oral small-molecule inhibitor of activated factor XI, may reduce the risk of non-cardioembolic ischemic stroke without increasing bleeding risk when added to standard antiplatelet therapy. A recent study published in […]